Arvinas (ARVN) EPS (Basic) Growth (1y) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) EPS (Basic) Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 87.85% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 143.95% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 322.67% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -16.29% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 96.41% |
| 10 | Arvinas | 608.15 Mn | 40.25 Mn | - | 411.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 411.82% |
| Mar 31, 2026 | -178.71% |
| Dec 31, 2025 | -51.55% |
| Sep 30, 2025 | 29.73% |
| Jun 30, 2025 | -71.24% |
| Mar 31, 2025 | 218.13% |
| Dec 31, 2024 | 77.51% |
| Sep 30, 2024 | 42.23% |
| Jun 30, 2024 | 59.96% |
| Mar 31, 2024 | 36.15% |
| Dec 31, 2023 | -85.25% |
| Sep 30, 2023 | 0.73% |
| Jun 30, 2023 | 3.62% |
| Mar 31, 2023 | -31.50% |
| Dec 31, 2022 | -63.30% |
| Sep 30, 2022 | -26.63% |
| Jun 30, 2022 | -23.25% |
| Mar 31, 2022 | -36.71% |
| Dec 31, 2021 | 5.99% |
| Sep 30, 2021 | -18.52% |